Table 5 Participants’ perceptions of sickle cell disease and hydroxyurea in relation to adherence laboratory markers in homozygous sickle cell patients (N = 29)
B-IPQ domains, median (IQR) | HbF% | MCV | ||||
|---|---|---|---|---|---|---|
Low <16% (n = 15) | High ≥16% (n = 14) | P-value | Low <102 (n = 15) | High ≥102 (n = 14) | P-value | |
Consequences | 6 (1, 8) | 5 (0, 7) | 0.69 | 7 (2, 9) | 3 (0, 5) | 0.05 |
Personal control | 5 (3, 10) | 5 (4, 8) | 0.82 | 5 (3, 7) | 5 (7, 9) | 0.32 |
Treatment control | 7 (5, 9) | 9 (7, 10) | 0.15 | 6 (5, 8) | 9 (7, 10) | 0.01 |
Identity (symptoms) | 6 (1, 8) | 4 (0, 6) | 0.2 | 6 (5, 8) | 1 (0, 4) | 0.01 |
Concerns | 7 (4, 9) | 5 (2, 9) | 0.48 | 6 (4, 9) | 5 (2, 8) | 0.44 |
Understanding | 10 (6, 10) | 9 (8, 10) | 0.83 | 10 (8, 10) | 10 (7, 10) | 0.65 |
Emotional response | 7 (0, 10) | 2 (0, 6) | 0.1 | 7 (3, 10) | 0 (0, 3) | <0.01 |